Additionally, an exploratory analysis from our recent prospective biomarker trial in GBM showed that the combination of MGMT promoter methylation and low CcO activity within tumors may be a predictive marker for longer patient survival [55]. This evidence concerns the gene MGMT and glioblastoma.